Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now full pipeline small index

Gastrointestinal Neoplasm: full-pipeline trial registry

3 of 5 indexed Gastrointestinal Neoplasm trials are currently recruiting.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 3 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Gastrointestinal Neoplasm: 5 US clinical trials tracked, 3 recruiting.

Gastrointestinal Neoplasm is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Baylor College of Medicine, running 2 of these trials.

Enrollment posture brief

Registry condition gastrointestinal-neoplasm

OPEN 3 | RECR 60% | LATE 1 | EARLY 1 | RANK #3391 | SPON 2

Nearest open-share peer: Acute Kidney Injury (AKI) (60% recruiting · 5 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Gastrointestinal Neoplas (th…60%
Open-enrollment share among volume-matched conditions near Gastrointestinal Neoplasm

Gastrointestinal Neoplasm lists 3 open slots (60% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Gastrointestinal Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Gastrointestinal Neoplasm is recruiting above its size-band peers.

    3 of 5 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Gastrointestinal Neoplasm research.

    Baylor College of Medicine accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Most Gastrointestinal Neoplasm trials plan to enrol fewer than 100 people.

    Median target enrolment is 66 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.

  4. Gastrointestinal Neoplasm research is mostly interventional.

    4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 31

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 3 1

Named interventions

Most-linked intervention names on Gastrointestinal Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Endoscopic Submucosal Dissection Procedure
2 trials
Continuous hyperthermic peritoneal perfusion (HIPEC/CHPP) Procedure
1 trials
Picoplatin Drug
1 trials
Traction Device Device
1 trials
Novel Rigidizing Overtube Device
1 trials
Cytoreductive surgery Procedure
1 trials
EUS-guided fine needle biopsy Diagnostic test
1 trials

US sites by state

Facility locations filed on Gastrointestinal Neoplasm trials. A trial with sites in several states counts in each.

Texas 2 trials
Washington 1 trials
Nevada 1 trials
Maryland 1 trials
Georgia 1 trials
Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Gastrointestinal Neoplasm page

5 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gastrointestinal Neoplasm condition card totals 5 registered trials; most-linked intervention Endoscopic Submucosal Dissection; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.